AbbVie (ABBV) Peer Comparison
$275.00
$2.58
(0.95%)
As on 09-Oct-2026 11:42EDT
Market cap
$459,327 Mln
Revenue (TTM)
$64,386 Mln
P/E Ratio
74.1
P/B Ratio
50.5
Div. Yield
2.6 %
Edit
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
459,327 | 1,024,927 | 617,006 | 354,804 | 268,096 |
Revenue ($ Mln) |
64,386 | 79,666 | 97,929 | 66,400 | 55,635 |
Net Profit ($ Mln) |
6,314.00 | 26,711.20 | 21,037.00 | 3,173.00 | 12,759.05 |
Net Margin (%) |
9.81 | 33.53 | 21.48 | 4.78 | 22.93 |
RoE (%) |
-- | 88.43 | 25.27 | 6.72 | 29.13 |
Price to Earnings |
74.05 | 38.91 | 30.02 | 115.98 | 21.31 |
Price-To-Book |
50.46 | 30.28 | 7.63 | 8.71 | 6.53 |
Income Statement ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
64,386.00 | 79,665.80 | 97,929.00 | 66,400.00 | 55,634.86 |
|
Cost of Revenue
|
18,365.00 | 13,225.00 | 31,428.00 | 16,350.00 | 14,220.25 |
|
Gross Profit
|
42,956.00 | 54,127.00 | 63,937.00 | 46,731.00 | 41,121.51 |
|
Operating Expenses
|
27,142.00 | 26,832.30 | 40,245.00 | 38,994.00 | 24,422.63 |
|
Operating Profit (EBIT)
|
18,879.00 | 39,608.50 | 26,256.00 | 11,056.00 | 16,991.98 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
8,699.00 | 33,595.60 | 25,196.00 | 5,948.00 | 15,524.68 |
|
Provision for Tax
|
2,383.00 | 6,884.40 | 4,159.00 | 2,779.00 | 2,775.63 |
|
Profit after Tax (Net Income)
|
6,314.00 | 26,711.20 | 21,037.00 | 3,173.00 | 12,759.05 |
|
Minority Interest
|
-6.00 | 0.00 | 0.00 | 4.00 | 10.00 |
|
Consolidated Profit
|
0.00 | 12,218.50 | 10,268.00 | 8,748.00 | 6,337.00 |
Liabilities ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-5,935.00 | 33,879.00 | 84,971.00 | 41,933.00 | 41,542.17 |
|
Minority Interest
|
-6.00 | 0.00 | 0.00 | 4.00 | 10.00 |
|
Non-Current Liabilities
|
99,361.00 | 60,663.00 | 61,195.00 | 60,087.00 | 48,339.19 |
|
Current Liabilities
|
41,642.00 | 47,741.00 | 54,895.00 | 27,731.00 | 31,748.13 |
|
Total Liabilities
|
133,960.00 | 112,476.00 | 199,210.00 | 136,866.00 | 115,569.20 |
Assets ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
101,446.00 | 77,611.00 | 141,286.00 | 93,123.00 | 94,682.38 |
|
Current Assets
|
33,669.00 | 64,672.00 | 59,774.00 | 36,679.00 | 27,351.11 |
|
Total Assets
|
133,960.00 | 112,476.00 | 199,210.00 | 136,866.00 | 115,569.20 |
|
Total Debt*
|
70,822.00 | 54,908.00 | 49,036.00 | 53,906.00 | 49,014.20 |
|
Net Current Assets
|
-7,973.00 | 16,931.00 | 4,879.00 | 8,948.00 | -4,397.00 |
Cashflow ($ Mln)
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
19,030.00 | 16,813.00 | 24,530.00 | 16,472.00 | 19,242.03 |
|
Cash Flow from Investing Activities
|
-6,643.00 | -10,972.00 | -23,588.00 | -13,741.00 | -4,901.98 |
|
Cash from Financing Activities
|
-12,724.00 | -2,213.00 | -5,539.00 | -1,922.00 | -14,943.13 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.17 | 35.32 | 22.56 | 19.45 | 17.74 |
|
ROE (%)
|
6,214.71 | 88.43 | 25.27 | 6.72 | 29.13 |
|
ROA (%)
|
3.57 | 16.19 | 8.36 | 2.11 | 8.80 |
|
EBIT Margin (%)
|
20.68 | 51.72 | 26.53 | 10.86 | 30.41 |
|
Net Margin (%)
|
9.81 | 33.53 | 21.48 | 4.78 | 22.93 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
10.39 | 49.58 | 8.06 | 4.24 | 0.81 |
|
EBIT Growth (%)
|
125.97 | 112.76 | -7.83 | -64.72 | 1.26 |
|
Net Profit Growth (%)
|
67.79 | 93.56 | -7.17 | -80.66 | -6.55 |
|
EPS Growth (%)
|
67.77 | 94.63 | -7.72 | -80.70 | -3.44 |
|
Book Value Growth (%)
|
-4,203.16 | 86.67 | 7.35 | -12.99 | 1.32 |
Valuation Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
95.92 | 46.76 | 18.83 | 14.35 | 18.92 |
|
Price / Book Value
|
-125.57 | 36.37 | 6.19 | 4.98 | 5.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
26.61 | 31.56 | 12.97 | 10.54 | 12.68 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-10.53 | 1.41 | 0.44 | 1.22 | 0.90 |
|
Short term debt to equity ratio
|
-1.41 | 0.21 | 0.14 | 0.07 | 0.24 |
|
Current Ratio
|
0.81 | 1.35 | 1.09 | 1.32 | 0.86 |
|
Quick Ratio
|
0.69 | 1.00 | 0.81 | 1.10 | 0.67 |
|
Interest Coverage
|
3.98 | 35.30 | 25.90 | 4.41 | 12.17 |
Operating Efficiency Ratios
| AbbVie (ABBV) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.47 | 29.47 | 19.45 | 18.92 | 17.71 |
|
Asset Turnover
|
0.36 | 0.48 | 0.39 | 0.44 | 0.38 |
|
Receivable days
|
70.20 | 93.67 | 70.00 | 64.57 | 63.79 |
|
Inventory Days
|
91.61 | 352.51 | 160.77 | 128.14 | 159.98 |
|
Payable days
|
65.58 | 142.23 | 134.61 | 85.14 | 120.44 |
|
Cash Conversion Cycle
|
96.23 | 303.95 | 96.16 | 107.57 | 103.33 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
